Effectiveness of Adding GLP ‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
Main finding · MAKEResult — go to the resultHazard ratio 0.70 95% CI 0.65–0.74Authors' conclusion
In this real-world CKD cohort, GLP-1RA added to SGLT2i therapy was associated with substantial incremental reductions in kidney disease progression and cardiovascular events.
Study context
- Population
- Adults with chronic kidney disease (CKD) treated with SGLT2i alone or SGLT2i with subsequent GLP-1 RA initiation, June 2020–December 2023, TriNetX Global Collaborative Networkmatched cohort
- Participants
- 32,448 adults
- Exposure
- SGLT2i plus subsequent GLP-1 RA vs SGLT2i monotherapy
- SGLT2i + GLP-1RAn = 16,224
- SGLT2i monotherapyn = 16,224reference
- Outcome
- Major adverse kidney events (MAKE)
- Follow-up
- Median 12 months
Methodological detailspropensity-score matched (1:1), TriNetX Global Collaborative Network
- Propensity-score matched (1:1)
- TriNetX Global Collaborative Network
Main finding
MAKE
Hazard ratio
0.70
95% CI 0.65–0.74
P < 0.001
SGLT2i + GLP-1RAvs SGLT2i monotherapy
HR 0.70 (95% CI 0.65–0.74); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
MACE · median follow-up 12 months
| HR (95% CI) | ||
|---|---|---|
| Combination therapyMatched cohort | 0.83 (0.78–0.87) | |
| 0.512Hazard ratio (log scale) |
All-cause mortality · median follow-up 12 months
| HR (95% CI) | ||
|---|---|---|
| Combination therapyMatched cohort | 0.55 (0.50–0.61) | |
| 0.512Hazard ratio (log scale) |
Major adverse kidney events (MAKE) by subgroup (CKD stage, diabetes status, obesity, HF, ischaemic heart disease)
- Benefits were consistent across CKD stages and diabetes status, with significantly more pronounced effects in patients with obesity, HF and ischemic heart disease
Safety
Adverse events
- Combination therapy associated with increased gastrointestinal symptoms, genital infections and retinopathy progression
- Combination therapy associated with lower risks of volume-depletion events and acute kidney injury
Original publication
Effectiveness of Adding GLP ‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study. Diabetes Obes Metab. Published 27 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →